NCT04777708 2023-03-24BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver CancerJonsson Comprehensive Cancer CenterPhase EARLY_PHASE1 Terminated1 enrolled
NCT03099564 2023-02-06Pembrolizumab Plus Y90 Radioembolization in HCC SubjectsHoosier Cancer Research NetworkPhase EARLY_PHASE1 Unknown30 enrolled